PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 1, 2024Journal of Clinical Oncology

Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).

View Full Paper
Ask AI
Bookmark
Share

Authors

TGTalia GolanJCJonathan CohenMVMark Voskoboynik

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates efficacy and safety of ILT3 antibody therapy in treatment-naive metastatic pancreatic cancer, suggesting improved outcomes.

Key Points

  • Confirmed overall response rate reached 43% with the four-drug combination in metastatic pancreatic ductal adenocarcinoma.
  • Median overall survival was notably improved, reported at 15.6 months following treatment with MK-0482 and chemotherapy.
  • Observational assessment included patients aged 18 or older with measurable disease, focusing on safety and efficacy outcomes over 13 months follow-up.

Cite This Study

Golan et al. (2024) studied this question.

synapsesocial.com/papers/68e671cdb6db6435875fc97fhttps://doi.org/10.1200/jco.2024.42.16_suppl.4139
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract CT104: Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors2024
  2. 2Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM).2024
  3. 3Abstract CT114: Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC)2024 · 1 citations
  4. 4Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.2024 · 4 citations
  5. 5Integrated NAL-IRI/5-FU/LV, benmelstobart, anlotinib with or without immunoradiotherapy for second-line metastatic pancreatic cancer: A phase II dual-cohort study.2026